About The Pharmaceutical Contract Development and Manufacturing Organization (CDMO)
The Contract Development and Manufacturing Organization (CDMO) industry is a prime sector in the global biopharmaceutical and pharmaceutical industry. CDMOs are third-party outsourcing companies that provide end-to-end drug development and manufacturing solutions for pharmaceuticals on a contract basis. This ranges from early-stage development of drugs (preclinical research, formulation, and clinical trials) to commercial-scale manufacturing, packaging, and even post-launch activities. CDMOs allow pharma companies—particularly those without in-house expertise or wishing to drive down costs—to get new drugs to market more economically and efficiently. The main applications of CDMOs are lowering time-to-market, minimizing R&D and manufacturing expenses, obtaining specialized expertise and technology, and enhancing scalability and flexibility of operations. This model is especially effective for small and mid-sized biopharma companies, which lack the infrastructure to enable full drug lifecycle management. Moreover, even big pharma companies use CDMOs to handle product overflow or enter new markets with minimal capital expenditures. The CDMO industry is experiencing strong growth fueled by the increasing drug molecule complexity, rising outsourcing trends, expansion in biologics and biosimilars demand, and drug development time pressure from regulators. It also has a critical role in producing advanced therapies, such as cell and gene therapies and mRNA vaccines.
Attributes | Details |
---|
Study Period | 2020-2032 |
Base Year | 2024 |
Unit | Value (USD Million) |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Lonza Group (Basel, Switzerland), Catalent Inc. ( Somerset, New Jersey, USA), Thermo Fisher Scientific (Patheon) (Waltham, Massachusetts, USA), WuXi AppTec ( Shanghai, China), Samsung Biologics (Incheon, South Korea), Recipharm AB (Stockholm, Sweden), Siegfried Holding AG ( Zofingen, Switzerland), Boehringer Ingelheim BioXcellence (Ingelheim am Rhein, Germany), Evonik Industries AG (Essen, Germany), Jubilant Pharmova (Noida, Uttar Pradesh, India), Cambrex Corporation (East Rutherford, New Jersey, USA), Piramal Pharma Solutions (Mumbai, Maharashtra, India), Curia (formerly AMRI) (Albany, New York, USA) and Alcami Corporation (Wilmington, North Carolina, USA) are some of the key players that are part of study coverage.
Segmentation Overview
AMA Research has segmented the market of Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market by and Region.
On the basis of geography, the market of The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
If we see Market by , the sub-segment i.e. will boost the The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.Influencing Trend:
Increased Focus on End-to-End Services and Technological Advancements
Market Growth Drivers:
Rising Demand for Outsourcing and Growth of Biologics and Biosimilars
Challenges:
Maintaining Quality Standards Globally and Volatility in Supply Chains
Restraints:
Regulatory Complexity and IP and Confidentiality Concerns
Opportunities:
Surging Demand for mRNA and Gene Therapies and Digital Transformation
Market Leaders and their expansionary development strategies
In March 2025, Shilpa Medicare introduced a "Hybrid CDMO" model at DCAT Week 2025. This approach combines comprehensive discovery, clinical, and commercial outsourcing services with ready-to-license novel formulations, focusing on oncology, peptides, and biologics. and In January 2025, Akums Drugs & Pharmaceuticals initiated the development of a new facility dedicated to lyophilized and sterile dosage manufacturing, emphasizing injectables and biologics.
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.